DOI: 10.1128/JCM.43.12.6000-6006.2005
Article Figures & Data
Figures
- FIG. 1.
Prevalence of T1762 and A1764 core promoter mutations in 200 genotype B and genotype C hepatitis B virus-infected patients with various liver diseases.
Tables
- TABLE 1.
Clinical features, HBV viremia, and prevalence of mutations in precore and core promoter regions in different clinical stages of chronic hepatitis B patients
Characteristic Asympatomatic carriers (n = 66) Chronic hepatitis patients (n = 95) Liver cirrhosis patients (n = 39) P value Age (yr) 31.7 ± 10.2 36.5 ± 11.3 45.3 ± 11.9 <0.001 Sex (no. of males:no. of females) 35:31 76:19 33:6 <0.005 ALT level (U/liter) 23.8 ± 9.8 186.6 ± 187.1 122.8 ± 126.8 NSa HBV DNA concn (log pg/ml) 2.4 ± 1.1 1.6 ± 1.1 0.001 HAI inflammation score 6.1 ± 3.6 6.4 ± 3.4 NS No. (%) of patients infected with HBV: Genotype B 52 65 14 <0.001 Genotype C 14 (21.1) 27 (29.3) 25 (64.1) T or G1752 28 (42.4) 35 (36.8) 8 (20.5) <0.05 C1753 0 3 (3.2) 7 (17.9) <0.001 T1762/A1764 11 (16.7) 32 (33.7) 34 (87.2) <0.001 T1766/A1768 1 (1.5) 7 (7.4) 6 (15.4) <0.01 T1773 8 (12.1) 4 (4.2) 1 (2.6) <0.05 C1799 48 (72.7) 67 (70.5) 15 (38.5) <0.005 T1846 14 (21.2) 17 (17.9) 12 (30.8) NS C1858 7 (10.6) 2 (2.1) 1 (2.6) <0.05 A1896 13 (19.7) 34 (35.8) 19 (48.7) <0.005 A1899 5 (7.5) 1 (1.1) 4 (10.3) NS ↵ a NS, not significant.
- TABLE 2.
Clinical features, HBV genotypes, HBV DNA levels, and liver inflammation in relation to HBeAg and clinical status
HBeAg and clinical status No. of patients Age (yr) Sex (no. of males:no. of females) No. infected with genotype B:no. infected with genotype C ALT level (U/liter) HBV DNA concn (log pg/ml) HAI inflammation score HAI fibrosis score HBeAg positive Asymptomatic carriers 28 31.6 ± 8.9 13:15 20:8 25.3 ± 13.2 Chronic hepatitis patients 59 34 ± 10.0a 45:14 37:19 201.9 ± 169.5 2.8 ± 1.0c 6.4 ± 3.7 0.8 ± 1.1 Liver cirrhosis patients 16 44.4 ± 12 15:1 4:12 87.5 ± 58.6 2.0 ± 1.2d 6.4 ± 4.5 4 Subtotal 103 35 ± 10.8b 73:30 61:39 136.1 ± 152.1 2.6 ± 1.1e 6.4 ± 3.8 1.5 ± 1.6f HBeAg negative Asymptomatic carriers 38 31.7 ± 11.3 22:16 32:6 22.8 ± 9.9 Chronic hepatitis patients 36 40.5 ± 12.1a 31:5 28:8 161.5 ± 212.9 1.7 ± 1.0c 5.6 ± 3.4 0.9 ± 1.2 Liver cirrhosis patients 23 45.8 ± 12 18:5 10:13 147.4 ± 154.6 1.3 ± 1.0d 6.4 ± 2.5 4 Subtotal 97 38.4 ± 12.9b 71:26 70:27 103.8 ± 162.3 1.5 ± 1.0e 5.9 ± 3.1 2.1 ± 1.8f - TABLE 3.
HBV precore and core promoter mutations in relation to HBeAg and clinical status
HBeAg and clinical status No. (%) of patients Total T or G1752 C1753 T1762/ A1764 T1766/A1768 T1773 C1799 T1846 C1858 A1896 A1899 HBeAg positive Asymptomatic carriers 28 14 (50) 0 2 (7.1) 0 1 (3.6) 20 (71.4) 1 (3.6)g 1 (3.6) 1 (3.6) 0 Chronic hepatitis patients 59 24 (40.7) 1 (1.7) 17 (28.8) 2 (3.4) 2 (3.4) 41 (69.5) 7 (11.9) 2 (3.4) 11 (18.6) 0 Liver cirrhosis patients 16 2 (12.5) 1 (6.2) 14 (87.5) 3 (18.7) 0 5 (31.3) 1 (6.2)h 1 (6.3) 3 (18.7) 0 Subtotal 103 40 (38.8) 2 (1.9)a 33 (32)b 5 (4.9) 3 (2.9)c 66 (64.1) 9 (8.8)d 4 (3.9) 15 (14.6)e 0f HBeAg negative Asymptomatic carriers 38 14 (36.8) 0 9 (23.7) 1 (2.6) 7 (18.4) 28 (73.7) 13 (34.2)g 6 (15.8) 12 (31.5) 5 (13.2) Chronic hepatitis patients 36 11 (30.5) 2 (5.5) 15 (41.6) 5 (13.9) 2 (5.5) 26 (72.2) 10 (27.8) 0 23 (63.8) 1 (2.8) Liver cirrhosis patients 23 6 (26.1) 6 (26.1) 20 (86.9) 3 (13) 1 (4.3) 10 (43.5) 11 (47.8)h 0 16 (69.6) 4 (17.4) Subtotal 97 31 (31.9) 8 (8.2)a 44 (45.4)b 9 (9.3) 10 (10.3)c 64 (66) 34 (35.1)d 6 (6.2) 50 (51.5)e 10 (10.3)f - TABLE 4.
Association of predictive factors with the risk of liver cirrhosis in patients with chronic hepatitis B virus infection
Factor OR (95% CI) Total (n = 200) HBeAg positive (n = 103) HBeAg negative (n = 97) Age ≥35 vs <35 yr 3.42 (1.33-8.77) 4.42 (1.03-19.0) Genotype C vs genotype B infection 2.87 (1.21-6.81) 4.01 (1.3-12.37) Presence vs absence of T1762 and A1764 mutant 11.11 (3.91-31.25) 16.95 (3.4-83.33) 11.36 (2.99-43.48)
